4//SEC Filing
Huang Andong 4
Accession 0001649989-25-000010
CIK 0001649989other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 8:37 PM ET
Size
8.6 KB
Accession
0001649989-25-000010
Insider Transaction Report
Form 4
Huang Andong
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-10-03+53,316→ 53,316 totalExercise: $1.06Exp: 2035-10-03→ Common Stock (53,316 underlying) - Award
Stock Option (Right to Buy)
2025-10-01+286,734→ 286,734 totalExercise: $1.04Exp: 2035-10-01→ Common Stock (286,734 underlying)
Footnotes (2)
- [F1]This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
- [F2]The options were granted under the 2024 Plan in lieu of $50,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
Related Parties
1- filerCIK 0001815678
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 8:37 PM ET
- Size
- 8.6 KB